Agenus’ (AGEN) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Agenus (NASDAQ:AGEN) in a report issued on Friday morning,Benzinga reports. HC Wainwright currently has a $7.00 price objective on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on the company. StockNews.com cut Agenus from a “hold” rating to a “sell” rating in a research note on Monday, August 12th. B. Riley reduced their price target on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. One analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, Agenus currently has an average rating of “Hold” and an average target price of $10.00.

Agenus Stock Down 2.0 %

Shares of NASDAQ AGEN opened at $3.42 on Friday. The stock has a market capitalization of $80.23 million, a P/E ratio of -0.30 and a beta of 1.39. The stock’s 50 day moving average price is $4.15 and its two-hundred day moving average price is $8.06. Agenus has a 52-week low of $2.50 and a 52-week high of $19.69.

Institutional Investors Weigh In On Agenus

Several large investors have recently added to or reduced their stakes in the stock. Point72 DIFC Ltd acquired a new position in shares of Agenus during the second quarter valued at $51,000. EP Wealth Advisors LLC bought a new stake in Agenus in the 3rd quarter valued at about $55,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Agenus during the 2nd quarter valued at about $106,000. HighTower Advisors LLC grew its position in Agenus by 46.1% in the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 7,530 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its stake in shares of Agenus by 52.0% in the third quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares during the period. 61.46% of the stock is owned by institutional investors and hedge funds.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.